Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus temozolomide and irinotecan versus temozolomide and irinotecan in pediatric recurrent or refractory Ewing sarcoma
2021-003444-25Phase 2Active
- Sponsor
- Pfizer
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of palbociclib in Ewing sarcoma (2 arms), sponsored by Pfizer. Primary endpoint: Event-free survival. Started Nov 2021; status: active.
02
Drugs
palbociclib
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on 2021-003444-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003444-25.